Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma

BACKGROUND: This phase II study assessed the response rate and toxicity profile of weekly paclitaxel and capecitabine in patients with metastatic or recurrent squamous cell carcinoma of the esophagus (SCCE) METHODS: Patients with histologically confirmed SCCE were treated with paclitaxel 80 mg/m(2 )...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Tak, Han, Ji-Youn, Lee, Jin Soo, Choi, Hyun Lee, Kim, Hyae Young, Nam, Byung-Ho, Kim, Heung Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176247/
https://www.ncbi.nlm.nih.gov/pubmed/21888637
http://dx.doi.org/10.1186/1471-2407-11-385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176247/
https://www.ncbi.nlm.nih.gov/pubmed/21888637
http://dx.doi.org/10.1186/1471-2407-11-385

Ejemplares similares